Updated 13/09/2026
South Africa’s drug regulator has announced an urgent recall of specific batches of Citro-Soda Regular following potential contamination risks at a Johannesburg manufacturing facility. The South African Health Products Regulatory Authority (SAHPRA) confirmed the precautionary measure affects products manufactured at the Adcock Ingram Clayville facility, according to SAHPRA’s March 20, 2026 announcement.
Regulatory response to manufacturing concerns
SAHPRA announced it will brief media on the recall following identification of potential contamination risks at the manufacturing site. The recall is being conducted as a precautionary measure to ensure patient safety, according to SAHPRA’s official statement.
The affected batches were produced at Adcock Ingram’s Clayville manufacturing facility in Johannesburg, as confirmed by SAHPRA. The regulatory authority has not disclosed the specific nature of the contamination risk or the total number of units affected by the recall.
Limited scope of safety action
The recall has been described by SAHPRA as limited in scope, affecting only specific batches rather than all Citro-Soda Regular products. This targeted approach suggests the contamination risk may be contained to particular production runs or time periods.
Further details about pharmaceutical quality and safety measures are expected to be provided during SAHPRA’s media briefing.
The recall is being conducted as a precautionary measure following identification of potential contamination risks at the Adcock Ingram Clayville manufacturing facility.
— South African Health Products Regulatory Authority (SAHPRA), March 20, 2026
Key takeaways
- SAHPRA has recalled specific batches of Citro-Soda Regular due to contamination concerns
- The recall affects products manufactured at Adcock Ingram’s Clayville facility in Johannesburg
- The action is described as precautionary and limited in scope to specific batches
Frequently asked questions
Which Citro-Soda products are affected by the recall?
The recall specifically affects Citro-Soda Regular products from certain batches manufactured at the Adcock Ingram Clayville facility, according to SAHPRA.
What type of contamination risk has been identified?
SAHPRA has not disclosed the specific nature of the contamination risk. More details are expected to be provided during the regulatory authority’s media briefing.
Should consumers stop using all Citro-Soda products?
The recall is limited to specific batches of Citro-Soda Regular only, according to SAHPRA. Consumers should check their product batch numbers and follow official guidance from healthcare authorities.
Source: SAHPRA to brief media on the recall of specified batches of Citro-Soda Regular amid safety concerns
{“@context”:”https://schema.org”,”@type”:”FAQPage”,”mainEntity”:[{“@type”:”Question”,”name”:”Which Citro-Soda products are affected by the recall?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”The recall specifically affects Citro-Soda Regular products from certain batches manufactured at the Adcock Ingram Clayville facility. Consumers should check batch numbers and await further guidance from SAHPRA.”}},{“@type”:”Question”,”name”:”What type of contamination risk has been identified?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”SAHPRA has not disclosed the specific nature of the contamination risk. More details are expected to be provided during the regulatory authority’s media briefing.”}},{“@type”:”Question”,”name”:”Should consumers stop using all Citro-Soda products?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”The recall is limited to specific batches of Citro-Soda Regular only. Consumers should check their product batch numbers and follow official guidance from healthcare authorities.”}}]}
🗺️ Find certified Georgian healthcare providers: sheniekimi.ge — Georgia Health Map · 998 clinics · 6,600+ doctors · 2,296 pharmacies
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
